Electra Therapeutics Receives FDA Orphan Drug Designation for ELA026 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)
SOUTH SAN FRANCISCO, CA, October 30, 2024 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation…
Electra Therapeutics to Present Clinical Data for ELA026 in the Treatment of sHLH in an Oral Session at the 2024 Annual Meeting of the Histiocyte Society
SOUTH SAN FRANCISCO, CA, October 29, 2024 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, announced today that the company will present clinical data for its lead drug candidate, ELA026…
Electra Therapeutics Presents Late-Breaking Clinical Data at EHA2024 from Ongoing Phase 1b Study of ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
SOUTH SAN FRANCISCO, CA, June 16, 2024 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, announced the presentation of clinical data for ELA026 in secondary hemophagocytic lymphohistiocytosis (sHLH), a life-threatening…
Electra Therapeutics to Present ELA026 Clinical Data in Late-Breaking Oral Session at the 2024 European Hematology Association (EHA) Congress
SOUTH SAN FRANCISCO, CA, June 3, 2024 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for a broad range of immunological diseases and cancer, announced today that clinical data for its lead drug candidate, ELA026, will be presented…
Electra Therapeutics Builds Leadership Team with Appointment of Dr. Graham Parry as Chief Scientific Officer and Dr. Kim-Hien Dao as Chief Medical Officer
SOUTH SAN FRANCISCO, CA, June 3, 2024 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for a broad range of immunological diseases and cancer, announced today the appointment of…
Electra Therapeutics presents first clinical data from ongoing Phase 1b study of ELA026 for treatment of secondary hemophagocytic lymphohistiocytosis (sHLH)
SOUTH SAN FRANCISCO, CA, December 11, 2023 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, announced the presentation of the first clinical data for ELA026…
Electra Therapeutics Appoints Kathy Dong, PharmD, MBA, as President and Chief Executive Officer
SOUTH SAN FRANCISCO, CA, December 11, 2023 – Electra Therapeutics, a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, today announced the appointment of Kathy Dong, PharmD, MBA, as President and…
Electra Therapeutics to Present Clinical Data for ELA026 at the American Society of Hematology (ASH) 2023 Annual Meeting
Company to reveal first clinical data from Phase 1b study of ELA026, its lead product candidate for life-threatening inflammatory disease, secondary hemophagocytic lymphohistiocytosis (sHLH) SOUTH SAN FRANCISCO, CA, November 2, 2023 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets, announced today that the company will present the initial […]
Electra Therapeutics highlights ELA026 Phase 1b study in sHLH and presents preclinical data at ASH Annual Meeting
Ongoing Phase 1b study progressing in US and EU for ELA026 in sHLH, a life-threatening inflammatory disease Preclinical data demonstrate ELA026 proof-of-mechanism of SIRP targeting and depletion of pathological immune cells that drive sHLH Company also presents results of sHLH natural history study SOUTH SAN FRANCISCO, CA, December 12, 2022 – Electra Therapeutics, Inc., a clinical […]
Electra Therapeutics to Highlight ELA026 in Three Presentations at the American Society of Hematology (ASH) 2022 Annual Meeting
Company’s lead product candidate, ELA026, is in a clinical study for a life-threatening inflammatory disease, secondary hemophagocytic lymphohistiocytosis (sHLH) SOUTH SAN FRANCISCO, CA, November 3, 2022 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies that target signal regulatory proteins (SIRP), announced today that the company will present three posters related to […]